Although most genetic alterations were conserved over time in our pediatric LGG cohort, changes in CDKN2A deletion status at recurrence or progression were observed in 11 patients (42% of patients who had this testing performed on paired tumor specimens), with acquisition of hemizygous CDKN2A deletions in seven patients and loss in four. This evidence concerns the gene CDKN2A and neoplasm.